<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AJH</journal-id>
<journal-id journal-id-type="hwp">spajh</journal-id>
<journal-id journal-id-type="nlm-ta">Am J Hosp Palliat Care</journal-id>
<journal-title>American Journal of Hospice and Palliative Medicine®</journal-title>
<issn pub-type="ppub">1049-9091</issn>
<issn pub-type="epub">1938-2715</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1049909111421608</article-id>
<article-id pub-id-type="publisher-id">10.1177_1049909111421608</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Pain Management in Hypertrophic Pulmonary Osteoarthropathy</article-title>
<subtitle> An Illustrative Case and Review</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Kilaru</surname>
<given-names>Malathy</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1049909111421608">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vitale</surname>
<given-names>Caroline</given-names>
</name>
<degrees>MD, AGSF</degrees>
<xref ref-type="aff" rid="aff2-1049909111421608">2</xref>
<xref ref-type="aff" rid="aff3-1049909111421608">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Montagnini</surname>
<given-names>Marcos</given-names>
</name>
<degrees>MD, FACP</degrees>
<xref ref-type="aff" rid="aff2-1049909111421608">2</xref>
<xref ref-type="aff" rid="aff3-1049909111421608">3</xref>
<xref ref-type="corresp" rid="corresp1-1049909111421608"/>
</contrib>
</contrib-group>
<aff id="aff1-1049909111421608"><label>1</label>Henry Ford Hospice, Henry Ford Health System, Detroit, MI, USA</aff>
<aff id="aff2-1049909111421608"><label>2</label>Division of Geriatric Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA</aff>
<aff id="aff3-1049909111421608"><label>3</label>Geriatrics Research and Education Clinical Center (GRECC), VA Ann Arbor Healthcare System, Ann Arbor, MI, USA</aff>
<author-notes>
<corresp id="corresp1-1049909111421608">Marcos Montagnini, Division of Geriatric Medicine, University of Michigan, VA Ann Arbor Healthcare System, GRECC (11-G), 2215 Fuller Road, Ann Arbor, MI 48105, USA Email: <email>mmontag@umich.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>29</volume>
<issue>4</issue>
<fpage>302</fpage>
<lpage>307</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Hypertrophic pulmonary osteoarthropathy (HOA) is a condition associated with lung cancer and many other diseases. Pain associated with HOA can be disabling, unremitting, and refractory to conventional analgesic medications. We present a challenging case of HOA in a patient with nonsmall cell lung cancer and review specific therapies for management of HOA-related pain.</p>
</abstract>
<kwd-group>
<kwd>pain</kwd>
<kwd>palliative care</kwd>
<kwd>pulmonary hypertrophic osteorthropathy</kwd>
<kwd>lung cancer</kwd>
<kwd>biphosphonates</kwd>
<kwd>vagotomy</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1049909111421608">
<title>Case Presentation</title>
<p>Mr MT is a 52-year-old man who presented with 2 weeks of severe pain and swelling affecting several joints, which prompted hospital admission for further workup and management. His symptoms initially began in both ankles then progressed to the feet, knees, hips, hands, wrists, elbows, and shoulders. He denied fever, chills, or other constitutional symptoms but reported a 25-pound weight loss over the last 6 months. His past medical history was significant for hypertension and sinusitis. He had a 20-pack-year tobacco history and had quit 25 years ago. His physical examination was unremarkable except for significant edema and warmth of the wrists, knees, ankles, and feet. Laboratory results revealed normal blood cell counts, comprehensive metabolic panel, C-reative protein (CRP), erythrocyte sedimentation rate (ESR), urinalysis, and rheumatoid factor. Chest x-ray showed mediastinal fullness, which was followed by a computed tomography (CT) scan, revealing a left upper lobe necrotic mass suspicious for malignancy. MT was discharged with acetaminophen and ibuprofen as needed for joint pain and was referred to the rheumatology and pulmonary clinics for further evaluation.</p>
<p>The outpatient workup for connective tissue disease was negative. Radiographs of the wrists, hands, and ankles revealed diffuse periostal reaction and soft tissue swelling, which were consistent with hypertrophic pulmonary osteoarthropathy (HOA). A bronchoscopy with biopsy and a positron-emission tomography (PET) scan demonstrated nonsmall cell lung cancer restricted to the chest. He was subsequently admitted postoperatively after a video-assisted thoracic surgery (VATS) procedure, during which tumor resection was deemed not feasible. During this short-stay admission, his pain was uncontrolled; he was started on a fentanyl patch (50 mcg/h), ibuprofen 800 mg 3 times daily, and his oxycodone–acetaminophen 5/325 was changed to oxycodone 10 mg every 4 hours as needed. He also began prednisone 20 mg daily. Upon presentation to the outpatient palliative care clinic 1 week later, he reported uncontrolled joint pain despite the use of this regimen. The fentanyl patch was then increased to 75 mcg/h, and oxycodone to 20 mg orally every 4 hours as needed for breakthrough pain. He also continued with prednisone 20 mg daily and ibuprofen as prescribed. His pain progressed despite this regimen, resulting in another hospital admission for pain control, where MT was started on an intravenous (IV) morphine continuous infusion, which was titrated up to 400 mg/d over the next few days to optimize pain control. A PET scan was repeated, demonstrating significant disease progression with distant metastases to his ribs, scapulae, femurs, abdominal lymph nodes, and left iliac crest.</p>
<p>Our patient received a dose of intravenous pamidronate (90 mg) for metastatic bone pain with hopes that it would also help control pain due to HOA. Four days after therapy with pamidronate, he was weaned off the IV morphine and started on a fentanyl patch (150 mcg/h), ibuprofen 600 mg 4 times daily, and morphine sulfate immediate release 15 to 30 mg every 4 hours as needed with good pain control. During this time period, the first cycle of palliative chemotherapy with cisplatin and etoposide was initiated, which he tolerated well. His pain remained under excellent control through the time of his discharge home at 9 days after the pamidronate dose. MT was discharged home with hospice, with plans to be evaluated for possible ongoing palliative chemotherapy. He did not receive subsequent bisphosphonate infusions. Although he remained comfortable at home with hospice services, MT died somewhat unexpectedly 4 days after his return home.</p>
</sec>
<sec id="section2-1049909111421608">
<title>Background</title>
<p>Hypertrophic pulmonary osteoarthropathy is a syndrome characterized by abnormal proliferation of the cutaneous and osseous tissues at the distal part of the extremities.<sup>
<xref ref-type="bibr" rid="bibr1-1049909111421608">1</xref>
</sup> This syndrome is classified as primary or secondary.<sup>
<xref ref-type="bibr" rid="bibr2-1049909111421608">2</xref>
</sup> The primary or familial form of HOA is inherited as an autosomal dominant trait and usually manifests in childhood, affecting primarily males.<sup>
<xref ref-type="bibr" rid="bibr3-1049909111421608">3</xref>
</sup> The secondary form is more common in adults and is associated with several conditions including lung cancer, cystic fibrosis, congenital heart disease, and a variety of other disorders,<sup>
<xref ref-type="bibr" rid="bibr3-1049909111421608">3</xref>,<xref ref-type="bibr" rid="bibr4-1049909111421608">4</xref>
</sup> as outlined in <xref ref-type="table" rid="table1-1049909111421608">Table 1</xref>. Among malignancy-related HOA, pulmonary malignancies compose 80% of reported HOA cases, the majority of which is nonsmall cell lung cancer such as squamous cell carcinoma or adenocarcinoma.<sup>
<xref ref-type="bibr" rid="bibr4-1049909111421608">4</xref>
</sup>
</p>
<table-wrap id="table1-1049909111421608" position="float">
<label>Table 1.</label>
<caption>
<p>Secondary Causes of Hypertrophic Pulmonary Osteoarthropathy<sup><xref ref-type="bibr" rid="bibr2-1049909111421608">2</xref>,<xref ref-type="bibr" rid="bibr4-1049909111421608">4</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table1-1049909111421608" xlink:href="10.1177_1049909111421608-table1.tif"/>
<table>
<tbody>
<tr>
<td>Pulmonary</td>
</tr>
<tr>
<td> Cystic fibrosis, pulmonary fibrosis, chronic infections, cancer  (primary or metastatic), arteriovenous fistulae, mesothelioma</td>
</tr>
<tr>
<td>Cardiac</td>
</tr>
<tr>
<td> Congenital cyanotic diseases, infective endocarditis</td>
</tr>
<tr>
<td>Vascular</td>
</tr>
<tr>
<td> Vascular prosthetic infections, aortic aneurysm, aortic prosthesis</td>
</tr>
<tr>
<td>Hepatic</td>
</tr>
<tr>
<td> Cirrhosis, carcinoma</td>
</tr>
<tr>
<td>Intestinal</td>
</tr>
<tr>
<td> Crohn disease, ulcerative colitis, chronic infections, laxative abuse,  polyposis, malignant tumors</td>
</tr>
<tr>
<td>Mediastinal</td>
</tr>
<tr>
<td> Esophageal carcinoma, thymoma, achalasia</td>
</tr>
<tr>
<td>Miscellaneous</td>
</tr>
<tr>
<td> Graves disease, thalassemia, malignancies, connective tissue diseases,  AIDS</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section3-1049909111421608">
<title>Pathogenesis</title>
<p>The pathologic hallmark of HOA is neoangiogenesis associated with edema and osteoblast proliferation in distal tubular bones, leading to subperiosteal new bone formation.<sup>
<xref ref-type="bibr" rid="bibr5-1049909111421608">5</xref>
</sup> The pathogenesis of HOA is still not completely understood, and several theories have been proposed based on the success of certain treatment modalities.<sup>
<xref ref-type="bibr" rid="bibr4-1049909111421608">4</xref>
</sup> An early theory suggests a neural mechanism based on the improvement of HOA symptoms following vagotomy.<sup>
<xref ref-type="bibr" rid="bibr6-1049909111421608">6</xref>
<xref ref-type="bibr" rid="bibr7-1049909111421608"/>
<xref ref-type="bibr" rid="bibr8-1049909111421608"/>–<xref ref-type="bibr" rid="bibr9-1049909111421608">9</xref>
</sup> A more recent theory suggests the role of platelets in the development of this condition.<sup>
<xref ref-type="bibr" rid="bibr1-1049909111421608">1</xref>,<xref ref-type="bibr" rid="bibr10-1049909111421608">10</xref>
</sup> This theory suggests that megakaryocytes and large platelet particles present in venous circulation are normally inactivated during their passage through the pulmonary capillary bed.<sup>
<xref ref-type="bibr" rid="bibr1-1049909111421608">1</xref>
</sup> In conditions associated with pathological shunting in the lung vasculature (eg, cyanotic heart disease), these particles subsequently reach the distal extremities where they release platelet-derived growth factor (PDGF) and other factors which lead to vascular proliferation, edema, and new bone formation.<sup>
<xref ref-type="bibr" rid="bibr1-1049909111421608">1</xref>
</sup> High levels of PDGF have been demonstrated in patients with primary and secondary forms of HOA.<sup>
<xref ref-type="bibr" rid="bibr11-1049909111421608">11</xref>
</sup>
</p>
<p>The cytokine vascular endothelial growth factor (VEGF) has also been postulated to be implicated in the pathogenesis of HOA.<sup>
<xref ref-type="bibr" rid="bibr1-1049909111421608">1</xref>,<xref ref-type="bibr" rid="bibr12-1049909111421608">12</xref>
</sup> Vascular endothelial growth factor is a powerful endothelial cell–stimulating factor, which is overexpressed in a wide variety of solid tumors and hypoxia. In addition to stimulating angiogenesis, this molecule is a potent stimulator of vascular permeability.<sup>
<xref ref-type="bibr" rid="bibr12-1049909111421608">12</xref>
</sup> Vascular endothelial growth factor has also been demonstrated to have direct effects on osteoblasts and osteoclasts and might play an important role in the stimulation of bone growth.<sup>
<xref ref-type="bibr" rid="bibr13-1049909111421608">13</xref>
</sup> Vascular endothelial growth factor is reported to be elevated in primary HOA and HOA associated with lung cancer.<sup>
<xref ref-type="bibr" rid="bibr1-1049909111421608">1</xref>
</sup>
</p>
<p>Prostaglandin E (PGE) has also been postulated in the pathogenesis of HOA. Studies demonstrated that PGE is associated with periostitis<sup>
<xref ref-type="bibr" rid="bibr14-1049909111421608">14</xref>,<xref ref-type="bibr" rid="bibr15-1049909111421608">15</xref>
</sup> and with the development of primary HOA in humans.<sup>
<xref ref-type="bibr" rid="bibr16-1049909111421608">16</xref>
</sup>
</p>
</sec>
<sec id="section4-1049909111421608">
<title>Clinical Presentation</title>
<p>The primary or familial form of HOA (3%-5% of all cases) manifests with clubbing, periostitis, glandular skin problems (eg, acne, hyperhidrosis, and seborrhea), and hypertrophic skin changes in the face and extremities.<sup>
<xref ref-type="bibr" rid="bibr17-1049909111421608">17</xref>
</sup> These changes usually progress for 5 to 20 years and remain stable or disappear afterward.<sup>
<xref ref-type="bibr" rid="bibr3-1049909111421608">3</xref>,<xref ref-type="bibr" rid="bibr17-1049909111421608">17</xref>
</sup>
</p>
<p>The secondary form of HOA is more common in adults and may progress rapidly. Clinical manifestations include clubbing, periostitis, and arthritis.<sup>
<xref ref-type="bibr" rid="bibr18-1049909111421608">18</xref>
</sup> Periostitis is usually accompanied by pain, edema, and erythema in the affected area. Symmetrical painful arthritis affecting the knees, wrists, elbows, ankles, and metacarpophalangeal joints is common. Small joint effusions may be present.<sup>
<xref ref-type="bibr" rid="bibr18-1049909111421608">18</xref>
</sup> Low-grade fever and muscle weakness may also occur.<sup>
<xref ref-type="bibr" rid="bibr18-1049909111421608">18</xref>
</sup>
</p>
</sec>
<sec id="section5-1049909111421608">
<title>Laboratory and Radiographic Findings</title>
<p>Laboratory findings in primary and secondary HOA are similar. The ESR and CRP are usually elevated. Rheumatoid factor and antinuclear antibody are negative. Serum alkaline phosphatase may be elevated when there is significant bone formation. Synovial fluid is characteristically noninflammatory, with a low white cell count (predominantly mononuclear), low protein content, and normal complement levels.<sup>
<xref ref-type="bibr" rid="bibr18-1049909111421608">18</xref>
</sup>
</p>
<p>Radiographs characteristically reveal diffuse periosteal thickening along the shafts of the long bones and less commonly in the phalanges. In longstanding disease, multiple layers of bone may be deposited in the subperiosteal region giving an “onion skin” appearance.<sup>
<xref ref-type="bibr" rid="bibr19-1049909111421608">19</xref>
</sup>
</p>
<p>Nuclear imaging with radionuclide polyphosphate bone scan often demonstrates a pericortical linear concentration of nuclide along the involved bone shaft with periarticular uptake, emphasizing the presence of periostitis and synovitis.<sup>
<xref ref-type="bibr" rid="bibr18-1049909111421608">18</xref>
</sup>
</p>
</sec>
<sec id="section6-1049909111421608">
<title>Management</title>
<p>Improvement of symptoms of HOA and in some cases actual reversal of underlying periostisis has been reported to occur with resection or treatment of an identified underlying malignancy.<sup>
<xref ref-type="bibr" rid="bibr4-1049909111421608">4</xref>,<xref ref-type="bibr" rid="bibr20-1049909111421608">20</xref>
<xref ref-type="bibr" rid="bibr21-1049909111421608"/>
<xref ref-type="bibr" rid="bibr22-1049909111421608"/>–<xref ref-type="bibr" rid="bibr23-1049909111421608">23</xref>
</sup> Often, many patients with metastatic malignancies are not candidates for surgical resection (as was the case with our patient) and may not be able to tolerate palliative chemotherapy due to poor functional status. When treatment directed at the underlying condition is not possible, the difficulty lies in controlling the pain and swelling associated with periostitis of HOA, which can be disabling, unremitting, and refractory to conventional analgesic medications.</p>
<p>Data regarding the effectiveness of various therapies for HOA pain are derived generally from case reports and case series; therefore, it is difficult to establish a definitive, standard therapeutic approach.<sup>
<xref ref-type="bibr" rid="bibr4-1049909111421608">4</xref>
</sup> Pharmacologic therapy generally includes conventional use of nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and glucocorticoids; however, relief of the intense arthralgia associated with HOA utilizing these approaches is variable.<sup>
<xref ref-type="bibr" rid="bibr4-1049909111421608">4</xref>,<xref ref-type="bibr" rid="bibr24-1049909111421608">24</xref>
</sup> Efficacy of cyclooxygenase 2 (COX-2) inhibitors,<sup>
<xref ref-type="bibr" rid="bibr24-1049909111421608">24</xref>
</sup> and other traditional NSAIDs, including indomethacin and ketorolac,<sup>
<xref ref-type="bibr" rid="bibr25-1049909111421608">25</xref>,<xref ref-type="bibr" rid="bibr26-1049909111421608">26</xref>
</sup> in relieving HOA pain symptoms has been observed in case reports and case series, invoking prostaglandins as mediators in HOA pathophysiology.<sup>
<xref ref-type="bibr" rid="bibr24-1049909111421608">24</xref>
</sup>
</p>
<p>A more recent approach to pain management in HOA includes bisphosphonates.<sup>
<xref ref-type="bibr" rid="bibr4-1049909111421608">4</xref>
</sup> Bisphosphonates have been observed through several case reports and case series to relieve pain and other symptoms associated with HOA in cases refractory to conventional analgesics. <xref ref-type="table" rid="table2-1049909111421608">Table 2</xref> summarizes case reports of HOA utilizing bisphosphonate therapy found through a comprehensive search via PubMed. The use of IV pamidronate and, more recently, IV zoledronic acid has been reported by several authors.<sup>
<xref ref-type="bibr" rid="bibr27-1049909111421608">27</xref>
<xref ref-type="bibr" rid="bibr28-1049909111421608"/>
<xref ref-type="bibr" rid="bibr29-1049909111421608"/>
<xref ref-type="bibr" rid="bibr30-1049909111421608"/>
<xref ref-type="bibr" rid="bibr31-1049909111421608"/>
<xref ref-type="bibr" rid="bibr32-1049909111421608"/>
<xref ref-type="bibr" rid="bibr33-1049909111421608"/>
<xref ref-type="bibr" rid="bibr34-1049909111421608"/>–<xref ref-type="bibr" rid="bibr35-1049909111421608">35</xref>
</sup> Bisphosphonates are known to act via potent osteoclast inhibition with resulting relief of bone pain and reduction in pathologic fracture risk, but the exact mechanism of action of bisphosphonates in HOA remains unclear. Bisphosphonate effects on plasma VEGF levels have been proposed as another mechanism through which pain may be improved in HOA,<sup>
<xref ref-type="bibr" rid="bibr33-1049909111421608">33</xref>
</sup> although further studies are needed. The duration of the effect of bisphosphonates on HOA pain appears to be 2 to 3 months as noted in case reports;<sup>
<xref ref-type="bibr" rid="bibr27-1049909111421608">27</xref>
<xref ref-type="bibr" rid="bibr28-1049909111421608"/>
<xref ref-type="bibr" rid="bibr29-1049909111421608"/>
<xref ref-type="bibr" rid="bibr30-1049909111421608"/>
<xref ref-type="bibr" rid="bibr31-1049909111421608"/>
<xref ref-type="bibr" rid="bibr32-1049909111421608"/>
<xref ref-type="bibr" rid="bibr33-1049909111421608"/>
<xref ref-type="bibr" rid="bibr34-1049909111421608"/>–<xref ref-type="bibr" rid="bibr35-1049909111421608">35</xref>
</sup> however, responses in some appear to be incomplete with one patient achieving substantial but temporary relief with each infusion repeated every 2 weeks.<sup>
<xref ref-type="bibr" rid="bibr28-1049909111421608">28</xref>
</sup>
</p>
<table-wrap id="table2-1049909111421608" position="float">
<label>Table 2.</label>
<caption>
<p>Case Reports: Effects of Biphosphonates on Hypertrophic Pulmonary Osteoarthropathy–Related Pain</p>
</caption>
<graphic alternate-form-of="table2-1049909111421608" xlink:href="10.1177_1049909111421608-table2.tif"/>
<table>
<thead>
<tr>
<th>References</th>
<th>Number of cases reported</th>
<th>Diagnosis </th>
<th>Age (years), gender</th>
<th>Medication (dose, mg)</th>
<th>Timeline for pain relief (days)</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="3">Speden et al<sup>
<xref ref-type="bibr" rid="bibr27-1049909111421608">27</xref>
</sup>
</td>
<td rowspan="3">3</td>
<td>Nonsmall cell lung cancer</td>
<td>65, female</td>
<td>Pamidronate (45)</td>
<td>8</td>
</tr>
<tr>
<td>Nonsmall cell lung cancer</td>
<td>50, female</td>
<td>Pamidronate (15)</td>
<td>60</td>
</tr>
<tr>
<td>Nonsmall cell lung cancer</td>
<td>72, female</td>
<td>Pamidronate (30)</td>
<td>1</td>
</tr>
<tr>
<td>Suzuma et al<sup>
<xref ref-type="bibr" rid="bibr28-1049909111421608">28</xref>
</sup>
</td>
<td>1</td>
<td>Metastatic breast cancer</td>
<td>44, female</td>
<td>Pamidronate (30)</td>
<td>7</td>
</tr>
<tr>
<td>Garske and Bell<sup>
<xref ref-type="bibr" rid="bibr29-1049909111421608">29</xref>
</sup>
</td>
<td>1</td>
<td>Cystic fibrosis</td>
<td>27, male</td>
<td>Pamidronate (30)</td>
<td>3</td>
</tr>
<tr>
<td>Amital et al<sup>
<xref ref-type="bibr" rid="bibr30-1049909111421608">30</xref>
</sup>
</td>
<td>1</td>
<td>Congenital heart disease</td>
<td>50, female</td>
<td>Pamidronate (60)</td>
<td>7</td>
</tr>
<tr>
<td>Mauricio et al<sup>
<xref ref-type="bibr" rid="bibr31-1049909111421608">31</xref>
</sup>
</td>
<td>1</td>
<td>Nonsmall cell lung cancer</td>
<td>43, male</td>
<td>Pamidronate (90)</td>
<td>4</td>
</tr>
<tr>
<td>Yao et al<sup>
<xref ref-type="bibr" rid="bibr32-1049909111421608">32</xref>
</sup>
</td>
<td>1</td>
<td>Interstitial lung disease</td>
<td>53, male</td>
<td>Pamidronate (90)</td>
<td>7</td>
</tr>
<tr>
<td>King and Nelson<sup>
<xref ref-type="bibr" rid="bibr33-1049909111421608">33</xref>
</sup>
</td>
<td>1</td>
<td>Nonsmall cell lung cancer</td>
<td>48, female</td>
<td>Zolendronic acid (4)</td>
<td>3</td>
</tr>
<tr>
<td>Jayakar et al<sup>
<xref ref-type="bibr" rid="bibr34-1049909111421608">34</xref>
</sup>
</td>
<td>1</td>
<td>Bilateral lung transplant</td>
<td>62, female</td>
<td>Zolendronic acid (5)</td>
<td>3</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The risks and benefits of bisphosphonates in patients with HOA are informed by experience with bisphosphonate use in other conditions. This class of medications has been shown to have demonstrated efficacy in relieving pain from bony metastatic disease; bisphosphonates are also routinely used in the treatment of osteoporosis and hypercalcemia of malignancy. Although patients with malignancies are thought to be at higher risk of adverse effects of bisphosphonates due to higher doses used, IV bisphosphonates are generally well tolerated. With prolonged use, major side effects associated with the use of bisphosphonates include hypocalcemia, renal toxicity, and osteonecrosis of the jaw. Other recognized associated side effects include flu-like symptoms, myalgia, bone pain, and/or joint pain. Although hypocalcemia does not occur in most patients with bisphosphonate treatment, those with renal failure, hypomagnesemia, low vitamin D levels, or hypoparathyroidism may be at increased risk.<sup>
<xref ref-type="bibr" rid="bibr36-1049909111421608">36</xref>,<xref ref-type="bibr" rid="bibr37-1049909111421608">37</xref>
</sup> Therefore, periodic monitoring of serum calcium, magnesium, and phosphate level as well as renal function is recommended during prolonged therapy.<sup>
<xref ref-type="bibr" rid="bibr36-1049909111421608">36</xref>,<xref ref-type="bibr" rid="bibr37-1049909111421608">37</xref>
</sup> Potential nephrotoxicity associated with IV bisphosphonates appears to be associated with higher doses and infusion durations of less than 15 minutes.<sup>
<xref ref-type="bibr" rid="bibr38-1049909111421608">38</xref>,<xref ref-type="bibr" rid="bibr39-1049909111421608">39</xref>
</sup> Current guidelines recommend that serum creatinine be monitored prior to administration of pamidronate or zoledronic acid,<sup>
<xref ref-type="bibr" rid="bibr40-1049909111421608">40</xref>
</sup> and the bisphosphonate therapy discontinued for a creatinine level &gt; 1.4 mg/dL. Reinsitution of therapy should include close monitoring and prolonged infusion time, in addition to carefully weighing risks and benefits of this therapy in patients with renal dysfunction. Furthermore, although osteonecrosis of the jaw has been found to be a recognized but uncommon complication associated with IV bisphosphonate therapy, evidence supports the use of preventative dental measures, including the completion of necessary dental work and waiting 6 to 8 weeks before starting IV bisphosphonate therapy.<sup>
<xref ref-type="bibr" rid="bibr41-1049909111421608">41</xref>
</sup> Due to these important considerations, the risks and benefits of bisphosphonates must be weighed in light of important potential benefits of effective pain and symptom management that may be provided to patients with HOA via this therapy.</p>
<p>During 1950s to 1960s, vagotomy via thoracotomy had been reported in several case reports and case series to achieve relief of pain and edema as well as and radiographic resolution of periostitis observed in HOA.<sup>
<xref ref-type="bibr" rid="bibr6-1049909111421608">6</xref>,<xref ref-type="bibr" rid="bibr7-1049909111421608">7</xref>,<xref ref-type="bibr" rid="bibr9-1049909111421608">9</xref>,<xref ref-type="bibr" rid="bibr10-1049909111421608">10</xref>,<xref ref-type="bibr" rid="bibr42-1049909111421608">42</xref>
</sup> These observations implied a vagal pathophysiologic mechanism, which had not seemed plausible in more recent times. Subsequently, the practice of vagotomy for HOA management fell out of favor. A recent essay summarizing the vagotomy case series from this era<sup>
<xref ref-type="bibr" rid="bibr43-1049909111421608">43</xref>
</sup> and a recent case report by Ooi et al<sup>
<xref ref-type="bibr" rid="bibr21-1049909111421608">21</xref>
</sup> in 2007 utilizing a VATS approach for vagotomy resulting in immediate and sustained pain relief have brought renewed attention to the possibility of a vagal mechanism, again raising the question of a potential role of vagotomy in the management of pain associated with HOA.<sup>
<xref ref-type="bibr" rid="bibr4-1049909111421608">4</xref>
</sup>
</p>
</sec>
<sec id="section7-1049909111421608">
<title>Novel Therapies</title>
<p>The 2 growth factors PDGF and VEGF are thought to possibly be released into the systemic circulation due to pathologic shunting around the pulmonary vasculature in HOA.<sup>
<xref ref-type="bibr" rid="bibr24-1049909111421608">24</xref>
</sup> It is thought that therapies directed at decreasing these growth factor levels may be useful in managing symptoms of HOA. In fact, gefetinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor has been shown to be effective in reducing HOA pain and reducing radiographic periostitis in at least 1 case report.<sup>
<xref ref-type="bibr" rid="bibr44-1049909111421608">44</xref>
</sup> This suggests that EGFR inhibitors such as gefetinib may be a promising option for the treatment of HOA symptoms.</p>
<p>Octreotide, a synthetic analogue of somatostatin, and inhibitor of growth hormone, has also been shown in case studies to be successful in alleviating HOA-related pain.<sup>
<xref ref-type="bibr" rid="bibr5-1049909111421608">5</xref>,<xref ref-type="bibr" rid="bibr45-1049909111421608">45</xref>
</sup> As more recent data are accumulating that implicate VEGF involvement in the pathogenesis of HOA, the effect of octreotide might be explained by its inhibition of the production of VEGF and, therefore, inhibition of subsequent endothelial proliferation. This VEGF inhibition may be a mechanism of symptom relief in HOA.<sup>
<xref ref-type="bibr" rid="bibr5-1049909111421608">5</xref>,<xref ref-type="bibr" rid="bibr45-1049909111421608">45</xref>
</sup>
</p>
</sec>
<sec id="section8-1049909111421608">
<title>Summary</title>
<p>Pain associated with HOA tends to be severe and often difficult to treat. Conventional approaches to pain management with NSAIDs and opioids are often used as initial approaches to pain management; however, these agents are not always effective for management of HOA-related pain. Alternate approaches for which there is evidence of efficacy via case reports for HOA-related pain management include biphosphonates, vagotomy, gefitinib, and octreotide. Our patient achieved good pain control after IV bisphosphonate administration, similar to other case reports. Although our patient also began his first cycle of palliative chemotherapy a few days after bisphosphonate administration, his pain began to improve substantially just prior to the start of chemotherapy, supporting the role of bisphosphonates in the management of his pain. However, it is possible that the initiation of palliative chemotherapy may also have contributed to his pain control.</p>
<p>Bisphosponates appear to result in improved pain control in most cases reported, with the duration of effect observed to be 2 to 3 months. We believe it is important for palliative care providers to be able to recognize HOA as an important pain syndrome associated with lung malignancies and other conditions and to understand current approaches to HOA-associated pain. Given the limitations in current data regarding treatment efficacy, more research is needed to better understand the pathophysiology and optimal treatment options in HOA.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-1049909111421608">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-1049909111421608">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1049909111421608">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Lavin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vargas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rivera-Vinas</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Hyperthrophic osteoarthropathy: a palindrome with a pathogenic connotation</article-title>. <source>Curr Opin Rheumatol</source>. <year>2008</year>;<volume>20</volume>(<issue>1</issue>):<fpage>88</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr2-1049909111421608">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Lavin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Matucci-Cerinic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jajic</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Pineda</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Hypertrhophi osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria</article-title>. <source>J Rheumatol</source>. <year>1993</year>;<volume>20</volume>(<issue>8</issue>):<fpage>1386</fpage>–<lpage>1387</lpage>.</citation>
</ref>
<ref id="bibr3-1049909111421608">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castori</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sinibaldi</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mingarelli</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lachman</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Rimoin</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Dallapiccola</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Pachydermoperiostosis: an update</article-title>. <source>Clin Genet</source>. <year>2005</year>;<volume>68</volume>(<issue>6</issue>):<fpage>477</fpage>–<lpage>486</lpage>.</citation>
</ref>
<ref id="bibr4-1049909111421608">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hojjati</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy</article-title>. <source>Clin Rheumatol</source>. <year>2011</year>;<volume>30</volume>(<issue>1</issue>):<fpage>7</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr5-1049909111421608">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ángel-Moreno Maroto</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Martínez-Quintana</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Suárez-Castellano</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pérez-Arellano</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF)</article-title>. <source>Rheumatology (Oxford)</source>. <year>2005</year>;<volume>44</volume>(<issue>10</issue>):<fpage>1326</fpage>–<lpage>1327</lpage>.</citation>
</ref>
<ref id="bibr6-1049909111421608">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Flavell</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Reversal of pulmonary hypertrophic osteoarthropathy by vagotomy</article-title>. <source>Lancet</source>. <year>1956</year>;<volume>270</volume>(<issue>6911</issue>):<fpage>260</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr7-1049909111421608">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huckstep</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Bodkin</surname>
<given-names>PE</given-names>
</name>
</person-group>. <article-title>Vagotomy in hypertrophic pulmonary osteoarthropathy associated with bronchial carcinoma</article-title>. <source>Lancet</source>. <year>1958</year>;<volume>2</volume>(<issue>7042</issue>):<fpage>343</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr8-1049909111421608">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yacoub</surname>
<given-names>MH</given-names>
</name>
</person-group>. <article-title>Cervical vagotomy for pulmonary osteoarthropathy</article-title>. <source>Br J Dis Chest</source>. <year>1965</year>;<volume>59</volume>:<fpage>28</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr9-1049909111421608">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yacoub</surname>
<given-names>MH</given-names>
</name>
</person-group>. <article-title>Vagotomy through mediastinoscopy for pulmonary osteoarthropathy</article-title>. <source>Br J Dis Chest</source>. <year>1966</year>;<volume>60</volume>(<issue>3</issue>):<fpage>144</fpage>–<lpage>147</lpage>.</citation>
</ref>
<ref id="bibr10-1049909111421608">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickinson</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>JF</given-names>
</name>
</person-group>. <article-title>Megakaryocytes and platelet clumps as the cause of finger clubbing</article-title>. <source>Lancet</source>. <year>1987</year>;<volume>2</volume>(<issue>8573</issue>):<fpage>1434</fpage>–<lpage>1435</lpage>.</citation>
</ref>
<ref id="bibr11-1049909111421608">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silveri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>De Angelis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Argentati</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Brecciaroli</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Muti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cervini</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Hypertrophic osteoarthropathy: endothelium and platelet function</article-title>. <source>Clin Rheumatol</source>. <year>1996</year>;<volume>15</volume>(<issue>5</issue>):<fpage>435</fpage>–<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr12-1049909111421608">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atkinson</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>SB</given-names>
</name>
</person-group>. <article-title>Vascular endothelial growth factor (VEGF)-A and platelet derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing</article-title>. <source>J Pathol</source>. <year>2004</year>;<volume>203</volume>(<issue>2</issue>):<fpage>721</fpage>–<lpage>728</lpage>.</citation>
</ref>
<ref id="bibr13-1049909111421608">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrara</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Vascular endothelial growth factor: basic science and clinical progress</article-title>. <source>Endocr Rev</source>. <year>2004</year>;<volume>25</volume>(<issue>4</issue>):<fpage>581</fpage>–<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr14-1049909111421608">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Letts</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Simons</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Prostaglandin-induced neonatal periostitis</article-title>. <source>J Pediatr Orthop</source>. <year>1994</year>;<volume>14</volume>(<issue>6</issue>):<fpage>809</fpage>–<lpage>813</lpage>.</citation>
</ref>
<ref id="bibr15-1049909111421608">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nagy</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>KA</given-names>
</name>
</person-group>
<etal/> <article-title>Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts</article-title>. <source>J Clin Invest</source>. <year>1994</year>;<volume>93</volume>(<issue>6</issue>):<fpage>2490</fpage>–<lpage>2496</lpage>.</citation>
</ref>
<ref id="bibr16-1049909111421608">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uppal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Diggle</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>IM</given-names>
</name>
</person-group>
<etal/> <article-title>Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hyperthrophic osteoartropathy</article-title>. <source>Nat Genet</source>. <year>2008</year>;<volume>40</volume>(<issue>6</issue>):<fpage>789</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr17-1049909111421608">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martinez-Lavin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Pineda</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Valdez</surname>
<given-names>T</given-names>
</name>
</person-group>
<etal/> <article-title>Primary hyperthrophic osteoarthropathy</article-title>. <source>Semin Arthritis Rheum</source>. <year>1988</year>;<volume>17</volume>(<issue>3</issue>):<fpage>156</fpage>–<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr18-1049909111421608">
<label>18</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Altman</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Tenenbaum</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Hypertrophic osteoarthropathy</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Harris</surname>
<given-names>ED</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Budd</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Genovese</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Firestein</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Sargent</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Sledge</surname>
<given-names>CB</given-names>
</name>
</person-group>, eds. <source>Kelley’s Textbook of Rheumatology.7th ed</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Elsevier Saunders</publisher-name>; <year>2005</year>.</citation>
</ref>
<ref id="bibr19-1049909111421608">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pineda</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Guerra</surname>
<given-names>J</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Weisman</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Resnick</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Martinez-Lavin</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>The skeletal manifestations of clubbing: a study in patients with cyanotic congenital heart disease and hypertrophic osteoartropathy</article-title>. <source>Semin Arthritis Rheum</source>. <year>1985</year>;<volume>14</volume>(<issue>4</issue>):<fpage>263</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr20-1049909111421608">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nahar</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Al-Shemmeri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hussain</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Secondary hypertrophic osteoarthropathy: new insights on pathogenesis and management</article-title>. <source>Gulf J Oncolog</source>. <year>2007</year>;<volume>1</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr21-1049909111421608">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ooi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Saad</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Moorjani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Amer</surname>
<given-names>KM</given-names>
</name>
</person-group>. <article-title>Effective symptomatic relief of hypertrophic pulmonary osteoarthropathy by video-assisted thoracic surgery truncal vagotomy</article-title>. <source>Ann Thorac Surg</source>. <year>2007</year>;<volume>83</volume>(<issue>2</issue>):<fpage>684</fpage>–<lpage>685</lpage>.</citation>
</ref>
<ref id="bibr22-1049909111421608">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Armstrong</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>McCausland</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>GD</given-names>
</name>
</person-group>. <article-title>Hypertrophic pulmonary osteoarthropathy (HPOA) (Pierre Marie-Bamberger syndrome): two cases presenting as acute inflammatory arthritis. Description and review of the literature</article-title>. <source>Rheumatol Int</source>.<year>2007</year>;<volume>27</volume>(<issue>4</issue>):<fpage>399</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr23-1049909111421608">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atkinson</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>McElwain</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Peckham</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>PP</given-names>
</name>
</person-group>. <article-title>Hypertrophic pulmonary osteoarthropathy in Hodgkin’s disease: reversal with chemotherapy</article-title>. <source>Cancer</source>. <year>1976</year>;<volume>38</volume>(<issue>4</issue>):<fpage>1729</fpage>–<lpage>1734</lpage>.</citation>
</ref>
<ref id="bibr24-1049909111421608">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kozak</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Milne</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Morrow</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Cuiffo</surname>
<given-names>BP</given-names>
</name>
</person-group>. <article-title>Hypertrophic osteoarthropathy pathogenesis: a case highlighting the potential role for cyclo-oxygenase-2-derived prostaglandin E2</article-title>. <source>Nat Clin Pract Rheumatol</source>. <year>2006</year>;<volume>2</volume>(<issue>8</issue>):<fpage>452</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr25-1049909111421608">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leung</surname>
<given-names>FW</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Indomethacin therapy for hypertrophic pulmonary osteoarthropathy in patients with bronchogenic carcinoma</article-title>. <source>West J Med</source>. <year>1985</year>;<volume>142</volume>(<issue>3</issue>):<fpage>345</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr26-1049909111421608">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blackwell</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bangham</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Melzack</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Trotman</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Treatment of resistant pain in hypertrophic pulmonary arthropathy with ketorolac</article-title>. <source>Thorax</source>. <year>1993</year>;<volume>48</volume>(<issue>4</issue>):<fpage>401</fpage>.</citation>
</ref>
<ref id="bibr27-1049909111421608">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Speden</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nicklason</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The use of pamidronate in hypertrophic pulmonary osteoarthropathy (HPOA)</article-title>. <source>Aust N Z J Med</source>. <year>1997</year>;<volume>27</volume>(<issue>3</issue>):<fpage>307</fpage>–<lpage>310</lpage>.</citation>
</ref>
<ref id="bibr28-1049909111421608">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suzuma</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group> <article-title>Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma</article-title>. <source>Anticancer Drugs</source>. <year>2001</year>;<volume>12</volume>(<issue>9</issue>):<fpage>731</fpage>–<lpage>734</lpage>.</citation>
</ref>
<ref id="bibr29-1049909111421608">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garske</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>SC</given-names>
</name>
</person-group>. <article-title>Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy</article-title> <article-title>in cystic fibrosis</article-title>. <source>Chest</source>. <year>2002</year>;<volume>121</volume>(<issue>4</issue>):<fpage>1363</fpage>–<lpage>1364</lpage>.</citation>
</ref>
<ref id="bibr30-1049909111421608">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amital</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Applbaum</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Vasiliev</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rubinow</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate</article-title>. <source>Clin Rheumatol</source>. <year>2004</year>;<volume>23</volume>(<issue>4</issue>):<fpage>330</fpage>–<lpage>332</lpage>.</citation>
</ref>
<ref id="bibr31-1049909111421608">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mauricio</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Francis</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Athar</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chaudhary</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gajra</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Hypertrophic osteoarthropathy masquerading as lower extremity cellulitis and response to bisphosphonates</article-title>. <source>J Thorac Oncol</source>. <year>2009</year>; <volume>4</volume>(<issue>2</issue>):<fpage>260</fpage>–<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr32-1049909111421608">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Brahn</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature</article-title>. <source>Semin Arthritis Rheum</source>. <year>2009</year>;<volume>38</volume>(<issue>6</issue>):<fpage>458</fpage>–<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr33-1049909111421608">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>King</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>Hypertrophic osteoarthropathy effectively treated with zoledronic acid</article-title>. <source>Clin Lung Cancer</source>. <year>2008</year>;<volume>9</volume>(<issue>3</issue>):<fpage>179</fpage>–<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr34-1049909111421608">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayakar</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Abelson</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>Q</given-names>
</name>
</person-group>. <article-title>Treatment of hypertrophic osteoarthropathy with zoledronic acid: case report and review of the literature</article-title>. <source>Semin Arthritis Rheum</source>. <year>2011</year>.</citation>
</ref>
<ref id="bibr35-1049909111421608">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guyot-Drouot</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Solau-Gervais</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cortet</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group> <article-title>Rheumatologic manifestations of pachydermoperiostosis and preliminary experience with bisphosphonates</article-title>. <source>J Rheumatol</source>. <year>2000</year>;<volume>27</volume>(<issue>10</issue>):<fpage>2418</fpage>–<lpage>2423</lpage>.</citation>
</ref>
<ref id="bibr36-1049909111421608">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chennuru</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Koduri</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Risk factors for symptomatic hypocalcaemia complicating treatment with zoledronic acid</article-title>. <source>Intern Med J</source>. <year>2008</year>;<volume>38</volume>(<issue>8</issue>):<fpage>635</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr37-1049909111421608">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunstan</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Felsenberg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Seibel</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease</article-title>. <source>Nat Clin Pract Oncol</source>. <year>2007</year>;<volume>4</volume>(<issue>1</issue>):<fpage>42</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr38-1049909111421608">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Beitz</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Renal failure with the use of zoledronic acid</article-title>. <source>N Engl J Med</source>. <year>2003</year>;<volume>349</volume>(<issue>17</issue>):<fpage>1676</fpage>–<lpage>1679</lpage>.</citation>
</ref>
<ref id="bibr39-1049909111421608">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perazella</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Markowitz</surname>
<given-names>GS</given-names>
</name>
</person-group>. <article-title>Bisphosphonate nephrotoxicity</article-title>. <source>Kidney Int</source>. <year>2008</year>;<volume>74</volume>(<issue>11</issue>):<fpage>1385</fpage>–<lpage>1393</lpage>.</citation>
</ref>
<ref id="bibr40-1049909111421608">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hillner</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Ingle</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Chlebowski</surname>
<given-names>RT</given-names>
</name>
<etal/>
</person-group> <article-title>American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer</article-title>. <source>J Clin Oncol</source>. <year>2003</year>;<volume>21</volume>(<issue>21</issue>):<fpage>4042</fpage>–<lpage>4957</lpage>.</citation>
</ref>
<ref id="bibr41-1049909111421608">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dimopoulos</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kastritis</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bamia</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid</article-title>. <source>Ann Oncol</source>. <year>2009</year>;<volume>20</volume>(<issue>1</issue>):<fpage>117</fpage>–<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr42-1049909111421608">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diner</surname>
<given-names>WC</given-names>
</name>
</person-group>. <article-title>Hypertrophic osteoarthropathy. Relief of symptoms by vagotomy in a patienh with pulmonary metastases from a lympho-epithelioma of the nasopharynx</article-title>. <source>JAMA</source>.<year>1962</year>;<volume>1</volume>
<volume>81</volume>:<fpage>555</fpage>–<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr43-1049909111421608">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Treasure</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Hypertrophic pulmonary osteoarthropathy and the vagus nerve: an historical note</article-title>. <source>J R Soc Med</source>. <year>2006</year>;<volume>99</volume>(<issue>8</issue>):<fpage>388</fpage>–<lpage>390</lpage>.</citation>
</ref>
<ref id="bibr44-1049909111421608">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sekikawa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Saijo</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takada</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yamawaki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Ohkawa</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma</article-title>. <source>Anticancer Res</source>. <year>2005</year>;<volume>25</volume>(<issue>3c</issue>):<fpage>2435</fpage>–<lpage>2438</lpage>.</citation>
</ref>
<ref id="bibr45-1049909111421608">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Spiller</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Faull</surname>
<given-names>CM</given-names>
</name>
</person-group>. <article-title>Treatment of resistant pain in hypertrophic pulmonary osteoarthropathy with subcutaneous octreotide</article-title>. <source>Thorax</source>. <year>1997</year>;<volume>52</volume>(<issue>3</issue>):<fpage>298</fpage>–<lpage>299</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>